Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CLTX-targeted CAR T lymphocytes CHM 1101

A preparation of autologous T lymphocytes genetically modified to express a chimeric antigen receptor (CAR) comprised of a CD28 co-stimulatory signaling domain fused to the zeta chain of the TCR/CD3 complex (CD3zeta) and coupled to chlorotoxin (CLTX), a 36-amino acid peptide derived from the venom of the deathstalker scorpion, with potential immunomodulating and antineoplastic activities. Upon administration of autologous CLTX-targeted CAR T lymphocytes CHM 1101, the CAR-T cells are re-directed to specific brain tumor cells through its tumor-targeting domain CLTX. CLTX targets and binds to the membrane-bound endopeptidase matrix metalloproteinase-2 (MMP-2), thereby inducing selective toxicity in MMP-2-expressing tumor cells. MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in the brain.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CLTX CAR-T cells CHM 1101
Code name:CHM 1101
CHM-1101
CHM1101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search